The Company (Detail)	3 Months Ended
	Mar. 31, 2020 Segment product	Sep. 30, 2019 USD ($)	May 31, 2019 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of FDA approved products | product	2
Number of operating segments | Segment	1
Revolving Credit Facility
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Maximum borrowing capacity		$ 200,000,000
Revolving Credit Facility | Delayed Draw Term Loan
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Maximum borrowing capacity		$ 100,000,000	$ 100,000,000